Anticancer Ruthenium Complexes in Drug ... - Ingenta Connect

5 downloads 0 Views 60KB Size Report
EDITORIAL. Anticancer Ruthenium Complexes in Drug Discovery and. Medicinal Chemistry. In today's world cancer has become a main cause of death [1].
Editorial

Mini-Reviews in Medicinal Chemistry, 2016, Vol. 16, No. 10

771

EDITORIAL

Anticancer Ruthenium Complexes in Drug Discovery and Medicinal Chemistry In today’s world cancer has become a main cause of death [1]. “During the first half of the 20th century, treatment of cancer is by use of surgery and radiotherapy may cure it to the some extent due to that many patients are died as a result of metastasis”. “There is no curative therapy is available for the most forms of disseminated cancers, so that the discovery and development of novel active chemotherapeutic agents is largely needed”. Among the searching for novel drugs, metal-based drugs are receiving much attention [2]. “Metal complexes provide a highly versatile platform for drug design”. Research in this area is expanding rapidly and some promising leads have emerged [3]. “After the success of platinum compound cisplatin, countless platinum- containing drug candidates soon entered clinical trials but there are only two other worldwide approved platinum compounds used in routine clinical therapy; carboplatin and oxaliplatin” [4]. “Despite their boom these platinum compounds are ineffective against many types cancer, especially platinum resistant tumors with some severe side effects, including nephrotoxicity, neurotoxicity and ototoxicity” [5]. In the search for other alternative metal compounds, Ruthenium compounds represent one of the great success stories of metals in medicine. “The present study deals with the new strategies for the development of novel ruthenium compounds and screened for the in vivo anticancer activity against transplantable murine tumor cell line EAC and in vitro anticancer activity against human cancer cell lines, their mechanism of action and structure activity relationships” [6-15]. REFERENCES [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15]

Xiaomei Ma, Herbert Yu. Global Burden of Cancer. Yale. J. Biol. Med., 2006, 79, 85-94. Anchuri S. S, Thota S, Yerra R, Devarakonda K. P, Dhulipala S. Novel Mononuclear Ruthenium(II) Compounds in CancerTherapy. Asian Pacific J. Cancer Prev., 2012, 13, 3293-3298. Romero-Canelón I, Sadler P. J. Next-Generation Metal Anticancer Complexes: Multitargeting via Redox Modulation. Inorg. Chem., 2013, 52, 1227612291. W. H. Ang, P. J. Dyson, Classical and non-classical ruthenium-based anticancer drugs: towards targeted chemotherapy, Eur. J. Inorg. Chem., 2006, 2006, 4003-4018. Clarke M. J. Ruthenium metallo pharmaceuticals. Cord. Chem. Rev., 2003, 236, 209-233. Thota S, Vallala S, Yerra R, Rodrigues D. A, Raghavendra N. M, Barreiro E. J., Synthesis, characterization, DNA binding, DNA cleavage, proteinbinding and cytotoxic activities of Ru(II) complexes. Int. J. Biol. Macromolec., 2016, 82, 663-670. Clavel C. M, Paunescu E, Nowak-Sliwinska P, Griffioen A. W, Scopelliti R, Dyson P. J. Discovery of a Highly Tumor-Selective Organometallic Ruthenium(II)−Arene Complex. J. Med. Chem., 2014, 57, 3546-3558. Thota S, Vallala S, Yerra R, Barreiro E. J. Design, synthesis, characterization, cytotoxic and structure activity relationships of novel Ru(II) complexes. Chin. Chem. Lett., 2015, 26, 721-726. Wee Han A, Paul J. D. Classical and Non-Classical Ruthenium-Based Anticancer Drugs: Towards Targeted Chemotherapy. Eur. J. Inorg. Chem., 2006, 20, 4003-4018. Karki S S, Thota S, Darj S. Y, Balzarini J, Clercq E. De. Synthesis, anticancer, and cytotoxic activities of some mononuclear Ru(II) compounds. Bioorg. Med. Chem., 2007, 15, 6632-6641. Thota S, Vallala S, Imran M, Mekala S, Anchuri S. S, Karki S. S, Yerra R, Balzarini J, Clercq E. De., Synthesis, spectroscopic characterization, in vitro cytotoxic and structure activity relationships of some mononuclear Ru(II) complexes. J. Coord. Chem., 2013, 66, 1031-1045. 12.Thota S, Karki S. S. Jayaveera K. N, Balzarini J, Clercq E. De. Synthesis, characterization, antitumor, and cytotoxic activity of mononuclear Ru(II) complexes. J. Coord. Chem., 2010, 63, 4332-4346. Thota S, Karki S. S. Jayaveera K. N, Balzarini J, Clercq E. De. Synthesis, antineoplastic and cytotoxic activities of some mononuclear Ru(II) complexes, J. Enzyme Inhib. Med. Chem., 2010, 25, 513-519. Clarke M. J. Ruthenium metallopharmaceuticals. Coord. Chem. Rev., 2003, 236, 209-233. Caruso F, Monti E, Matthews J, et al., Synthesis, Characterization, and Antitumor Activity of Water-Soluble (Arene)ruthenium(II) Derivatives of 1,3Dimethyl-4-acylpyrazolon-5-ato Ligands. First Example of Ru(arene)(ligand) Antitumor Species Involving Simultaneous Ru−N7(guanine) Bonding and Ligand Intercalation to DNA. Inorg. Chem. 2014, 53, 3668-3677.

Dr. Sreekanth Thota Guest Editor: Mini-Reviews in Medicinal Chemistry National Institute for Science and Technology on Innovation on Neglected Diseases (INCT/IDN), Center for Technological Development in Health (CDTS), Fundação Oswaldo Cruz Ministério da Saúde, Av. Brasil 4036 - Prédio da Expansão, 8º Andar - Sala 814, Manguinhos, 21040-361 Rio de Janeiro - RJ – Brazil